PUMAi
PUMAi is a PUMA inhibitor that disrupts the interaction between PUMA and BCL-xL. PUMAi inhibits apoptosis, caspase-3 activation, WNT/NOTCH pathway activation, and DNA damage. PUMAi protects intestinal tissues in mice, promotes the growth of colonoids, and reduces chemotherapy-induced weight loss, gastrointestinal damage, and lethality. PUMAi alleviates acetaminophen-induced liver injury and cytoplasmic translocation of HMGB1 in mice. PUMAi can be used in studies related to gastrointestinal injury, intestinal injury, and liver injury.
For research use only. We do not sell to patients.
- CAS No.: 470695-03-5
- Formula: C19H28Cl2N2O3
- Molecular Weight:403.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Caspase 3 |
Bcl-xL |
In Vitro
PUMAi (25 μM; 15 min) inhibits the protein-protein interaction between PUMA and BCL-xL in HEK293 cell lysates, without affecting the interaction between BIM and MCL-1[1].
PUMAi (50 μM; 24 h) protects mouse colon organoids and human primary colon organoids from CPT-induced growth inhibition, apoptosis, and WNT/Notch pathway activation[1].
PUMAi effectively disrupts the interaction between PUMA and BCL-XL in cell-free biochemical assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
PUMAi (10 mg/kg; i.p.; 2 hours before CPT-11) reduces LGR5+ intestinal stem cell apoptosis, niche cell expansion, and DNA damage in mice treated with CPT-11[1].
PUMAi (10 mg/kg; i.p.; 2 hours before and 20 hours after each of 6 CPT-11 doses) prevents LGR5+ intestinal stem cell exhaustion and preserves niche integrity in mice treated with repeated doses of CPT-11[1].
PUMAi (10 mg/kg; i.p.; 2 hours before and 20 hours after each of 6 CPT-11 doses) protects tumor-bearing mice from CPT-11-induced gastrointestinal injury and weight loss without compromising tumor response to chemotherapy[1].
PUMAi (10 mg/kg; i.p.; 30 minutes before irradiation, 30 minutes after irradiation, and daily for 4 subsequent days) improves survival in mice with radiation-induced gastrointestinal injury[1].
PUMAi (10 mg/kg; i.p.; single dose) administered 2 hours after acetaminophen overdose significantly reduces acetaminophen-induced liver necrosis and injury in mice, as evidenced by reduced serum ALT/AST levels, necrotic liver area, TUNEL-positive cells, and HMGB1 cytoplasmic translocation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 470695-03-5
-
Molecular Weight 403.34
-
Formula C19H28Cl2N2O3
-
SMILES
OCCN1CCN(CC(COC2=CC3=C(C=CC=C3)C=C2)O)CC1.Cl.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Detection of Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Notch Pathway Solutions
The Notch pathway is a contact-dependent signaling pathway that controls cell-fate decisions, differentiation, proliferation, and tissue patterning through interactions between membrane-bound Notch receptors and membrane-bound ligands on neighboring cells. Canonical Notch signaling is activated when ligand engagement triggers proteolytic release of the Notch intracellular domain, which enters the nucleus and regulates transcription together with DNA-binding transcriptional complexes. In the canonical mechanism, ligand-dependent Notch activation leads to release of the intracellular Notch domain, and presenilin-dependent γ-secretase activity is required for production of the active intracellular signaling fragment. The released intracellular domain functions as a nuclear signal that converts Notch receptor activation at the membrane into transcriptional regulation of target programs such as HES/HEY-family genes and other context-dependent downstream targets. The literature links Notch p
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)